Isis surges on promising head-to-head thrombosis drug study

John Carroll

Shares of Pharmaceuticals surged 9% this morning as the Carlsbad, CA-based antisense developer posted positive outcomes for a head-to-head Phase II comparing ISIS-FXIRx with Lovenox on . The biotech says the top 300 mg dose of its therapy beat out the widely used anticoagulant, lowering the number of blood clots while reducing the number of bleeding incidents.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS